Tarsus Pharmaceuticals (TARS) Other Non-Current Liabilities (2019 - 2026)

Tarsus Pharmaceuticals' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $16.1 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $16.1 million in Q1 2026; TTM through Mar 2026 was $16.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $10.6 million, changed N/A from the prior year.
• Other Non-Current Liabilities climbed to $16.1 million in Q1 2026 per TARS's latest filing, from $10.6 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $16.1 million in Q1 2026 and bottomed at $40000.0 in Q1 2023.
• The 5-year median for Other Non-Current Liabilities is $1.5 million (2024), against an average of $3.4 million.
• Across the five-year window, Other Non-Current Liabilities tumbled 91.94% in 2023 and jumped 3915.0% in 2024, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $100000.0 in 2022, then soared by 1648.0% to $1.7 million in 2023, then declined by 29.06% to $1.2 million in 2024, then jumped by 754.76% to $10.6 million in 2025, then surged by 51.7% to $16.1 million in 2026.
• Per Business Quant, the three latest TARS Other Non-Current Liabilities figures stand at $16.1 million (Q1 2026), $10.6 million (Q4 2025), and $10.1 million (Q3 2025).